Ninlaro

Chemical Nameixazomib
Dosage FormCapsule (oral; 2.3 mg, 3 mg, 4 mg)
Drug ClassInhibitors
SystemBlood
CompanyMillennium Pharms
Approval Year2015

Indication

  • In combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Last updated on 10/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ninlaro (ixazomib) Prescribing Information2020Takeda Pharmaceutical Company Limited, Cambridge, MA